Skip To Main Content
Tanner W. Reicks on Muck Rack

Tanner W. Reicks

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Tanner W.

Contact Tanner W., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Treatment patterns and outcomes for second-line therapy in large B-cell lymphoma: results from the LEO CReWE study

|
By Jean L. Koff, Melissa Larson, Jonathon Cohen, Izidore S. Lossos, Peter Martin, Thomas M Habermann, Carla Casulo, Samuel Yamshon, Andrea Lo-Rossi, Connie Lee Batlevi, Anthony Masaquel, Yong Mun, Yucai Wang, Arushi Khurana, Grzegorz Nowakowski, Dai Chihara, Eric Mou, Umar Farooq, Dilan A. Patel, Amy Ayers, James R. Cerhan, Christopher Flowers, Matthew J. Maurer, Loretta J Nastoupil, Ashwini Shewade, Tanner W. Reicks
| Nature Verified
Abstract Treatment strategies for relapsed/refractory large B-cell lymphoma (R/R LBCL) have evolved rapidly, yet relationships between therapy selection and outcomes remain poorly defined. The LEO CReWE study evaluated disease characteristics, patterns of care, and outcomes in 1504 patients with R/R LBCL from 2002 to 2022. Of these, 64% received chemoimmunotherapy at second-line (2L).
Open in Who Shared Issue with article?
See all 1 articles